

Delta4 Secures European Patents for Two Compounds as Candidate Treatments for Focal Segmental Glomerulosclerosis (FSGS)

AI and Computational Biology accelerate breakthrough therapy options: Delta4's Latest Milestone

VIENNA, VIENNA, AUSTRIA, February 10, 2025 /EINPresswire.com/ -- [Delta4](#), a leader in AI-driven drug discovery and indication expansion, is proud to announce that it has been granted European patents for two innovative compounds positioned as candidate treatments for focal segmental glomerulosclerosis ([FSGS](#)), a rare and serious kidney disease. These patents mark a significant milestone in Delta4's mission to accelerate the delivery of groundbreaking therapies leveraging AI through advanced computational biology.

“

We are excited to continue with clinical trials, taking these compounds to market, and ultimately providing new therapeutic options that improve the quality of life for those affected by FSGS.”

Kurt Herpel

** Anti-inflammatory, anti-fibrotic, and immune-modulating effects, addressing key mechanisms of FSGS progression.



The graphic features the Delta4 logo (a stylized fan icon) and the text "Delta4 digital drug discovery & development". Below this, it states "2 EU Patents Granted for the Treatment of FSGS". To the right is a photograph of several blue, round tablets. At the bottom left, there is a call to action: "Be Sure To Visit Our Website!". In the background, there are faint chemical structures and a molecular diagram.

Delta4 secures two EU patents for innovative FSGS treatments, advancing drug repurposing for rare kidney diseases.

The newly patented compounds include:

1.) Clopidogrel: Already approved for cardiovascular conditions, clopidogrel has been identified by Delta4's proprietary AI platform, [Hyper-C](#), as a promising candidate for FSGS. In animal models, clopidogrel demonstrated:

** A 61% reduction in the urinary albumin to creatinine ratio (UACR), a critical marker of kidney function.

** Significant improvements in histopathological damage, with a 67.9% reduction in kidney damage scores.

2.) Combination of Saroglitazar and Myristic Acid (Saro+Myr): This novel combination leverages the dual PPAR agonist properties of saroglitazar and the calcineurin-inhibiting effects of myristic acid. The Saro+Myr combination exhibited:

** Significant reductions in proteinuria and UACR in multiple FSGS animal models.

** Improvements in kidney pathology, including reduced glomerular sclerosis and tubular ectasia.


** Synergistic therapeutic effects targeting inflammation, fibrosis, and disease progression.

A Testament to AI-Driven Innovation
These breakthroughs are the result of Delta4's cutting-edge Hyper-C platform, which analyzes vast biomedical datasets to identify subtle molecular relationships between diseases and drugs. Hyper-C's ability to predict mechanisms of action (MoA) and therapeutic efficacy was instrumental in repositioning clopidogrel and discovering the synergistic potential of the Saro+Myr combination.

"We are proud to have been granted these patents, which are a testament to the power of our AI-driven platform, Hyper-C. The success of these compounds in animal models underscores the accuracy and reliability of our AI-driven approach," said Kurt Herpel, CEO of Delta4. "We are excited to continue with clinical trials, taking these compounds to market, and ultimately providing new therapeutic options that improve the quality of life for those affected by FSGS."

From Breakthroughs to Better Outcomes


Delta4 is collaborating with partners to advance these compounds into clinical trials. The company expects the trials to replicate the success observed in preclinical studies, further validating the predictions made by Hyper-C.



Delta4

digital drug discovery & development

Delta4 is a digital drug discovery TechBio company founded in Vienna, Austria, specializing in AI-driven drug repurposing and indication expansion.



Delta4 utilizes its proprietary Hyper-C platform to accelerate the identification of new therapeutic applications for existing compounds.

For more information about Delta4 and its groundbreaking work in AI-powered drug discovery, please visit <https://delta4.ai/>.

Delta4 is a digital drug discovery TechBio company founded in 2019 in Vienna, Austria. Specializing in AI-driven drug repurposing and indication expansion, Delta4 utilizes its proprietary Hyper-C platform to accelerate the identification of new therapeutic applications for existing compounds. Focused on tackling complex and rare diseases, Delta4 collaborates with pharmaceutical companies, universities, and clinics to bring innovative treatments to market efficiently.

Kurt Herpel
Delta4
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/783939737>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.